BioSpace News Archive

Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose.

bitBiome, Inc. (Head office: Shinjuku-ku, Tokyo; President: Yuji Suzuki; hereafter ‘bitBiome’) and Kaken Pharmaceuticals (Head office: Bunkyo-ku, Tokyo; President: Hiroyuki Horiuchi; hereafter ‘Kaken’) have signed a joint research agreement on the discovery of drugs for infectious diseases with high unmet medical needs.

Inimmune announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., and its Chief Operating Officer, David Burkhart, Ph.D., will play key roles at the World Vaccine Congress event.

LifeTech Scientific Corporation, a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, announced its 2022 annual results.

Oragenics, Inc., a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.

On March 29, 2023, Broncus Medical, a leader in precise interventional diagnosis and therapy of lung diseases in China, announced its annual results for the year ended December 31, 2022.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce it has engaged Montreal’s RobboDesign to revise and search engine optimize its website, to engage with critical limb ischemia “CLI” and peripheral arterial disease “PAD” patients, globally.

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today reported positive topline data from the company’s recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company presented Phase 1 data for its thyroid receptor-beta (THR-ß) agonist candidate, ALG-055009, at the 15th Paris Hepatology Conference, taking place virtually March 27 – 29, 2023.